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Abstract
The European Medicines Agency has in recent years allowed licensing of new pharmaceuticals at an earlier
stage in the clinical trial process. When trial evidence is obtained at an early stage, the events of interest,
such as disease progression or death, may have only been observed in a small proportion of patients.
Health care authorities therefore must decide on the adoption of new technologies based on less mature
evidence than previously, resulting in greater uncertainty about clinical- and cost-effectiveness. When a
trial is ongoing at the point of decision making, there may be value in continuing the trial in order to
collect additional data before making an adoption decision. This can be quantified by the Expected Value
of Sample Information (EVSI). However, no guidance exists on how to compute the EVSI for survival data
from an ongoing trial, nor on how to account for uncertainty about the choice of survival model in the
EVSI calculations. In this article, we describe algorithms for computing the EVSI of extending a trial’s
follow-up, both where a single known survival model is assumed, and where we are uncertain about the
true survival model. We compare a nested Markov Chain Monte Carlo procedure with a non-parametric
regression-based method in two synthetic case studies, and find close agreement between the two methods.
The regression-based method is fast and straightforward to implement, and scales easily to include any
number of candidate survival models in the model uncertainty case. EVSI for ongoing trials can help
decision makers determine whether early patient access to a new technology can be justified on the basis
of the current evidence or whether more mature evidence is needed.
Introduction
The Expected Value of Sample Information (EVSI) quantifies the expected value to the decision maker of
reducing uncertainty through the collection of additional data,1,2 for example a future randomised controlled
trial. Although a few studies have considered the use of EVSI methods at interim analyses of adaptive trials,3
overall little research has been done on EVSI for trials that are ongoing at the point of decision making.
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In the last decade the European Medicines Agency (EMA) has introduced regulatory mechanisms that
are aimed at accelerating licensing of new pharmaceuticals, such as ‘adaptive pathways’4 and ‘conditional
marketing authorisations.’5 When evidence is obtained from a trial at an early stage, the events of interest,
such as disease progression or death, may have only been observed in a small proportion of patients. Health
care authorities therefore have to issue guidance on new pharmaceuticals based on less mature evidence than
previously, resulting in greater uncertainty about clinical- and cost-effectiveness. With this comes an increased
risk of recommending a technology that reduces net health benefit.6
Additional evidence can be valuable as it can lead to better decisions that improve health and/or reduce
resource use.6 Positive adoption decisions can be costly or difficult to reverse, and may remove the incentives
for manufacturers to provide additional data. When a trial is ongoing at the point of decision making, for
example when follow-up is continued for regulatory purposes, there may therefore be value in delaying the
adoption decision until additional data has been collected in the ongoing trial and uncertainty has reduced.7
In this context, there will be a trade-off between granting early access to a new technology that may turn out
to reduce health benefits, and waiting for uncertainty to be reduced through ongoing data collection with a
potential loss of health benefits while waiting. When the manufacturer is already committed to continuing the
ongoing trial, the option to delay a decision is relevant even in a policy context where the decision maker does
not have the formal authority to commission research. The value of delaying the decision could be quantified,
at least in theory, by computing the EVSI for the additional follow-up data.
Estimates of life-expectancy and time to disease progression are often key drivers of cost-effectiveness,
particularly in oncology. However, immature data means that there may be substantial uncertainty around
these estimates and they rely on extrapolation beyond the trial follow-up period.8 The choice of the survival
distribution for extrapolation can have major implications for cost-effectiveness, and uncertainty surrounding
this choice can be accounted for by model averaging, which may improve the quality of the extrapolations
compared to selecting a single model.9 A potential benefit of continuing an ongoing trial is to reduce the
structural uncertainty as to the most appropriate survival distribution. However, to the best of the authors
knowledge, there exists no guidance on how to compute EVSI for survival data from a trial that is ongoing at
the point of decision making, nor on how to account for structural uncertainty about the choice of survival
model in the EVSI calculations.
In this article, we present algorithms for computing the EVSI of extending a trial’s follow-up with and
without accounting for structural uncertainty. The algorithms are based on nested Markov Chain Monte
Carlo methods and a fast nonparametric regression-based method.10 The nonparametric regression-based
method10 is generally more practical than other EVSI approximation methods as it neither requires nested
Monte Carlo computations nor importance sampling.11 The article is structured as follows. In the second
section, we describe single-model and model-averaged EVSI algorithms for survival data from an ongoing trial.
In the third section, we compare the EVSI algorithms in two illustrative case studies, and in a final section,
conclude with a brief discussion.
Method
EVSI for an ongoing study collecting time-to-event data
Decision problem and model definition
We assume a decision problem with d = 1, . . . , D decision options. The net benefit of option d is NB(d, θ),
and we have a cost-effectiveness model that predicts this quantity, given a vector of p possibly correlated
model input parameters, θ = {θ1, . . . , θp}. Our current judgements about the vector θ is represented by the
joint probability distribution p(θ). Our goal is to choose the decision option with the greatest net benefit.
EVSI for further follow-up in an ongoing study
The EVSI for a new study that will provide (as yet uncollected) data, x, is defined as:
EVSI(new study) = Ex[max
d




where the first term is the expected value of a decision based on our beliefs about θ given the new data,
p(θ|x), and the second term is the expected value of a decision based on our beliefs about θ given current
information alone, p(θ).12 We now imagine that data x have been collected during a given follow-up period for
this study, which we denote time t1. This could be an interim analysis, or the end of the study follow period.
The value of extending follow-up from current time t1 to some future point t2 is given by
EVSI(ongoing study) = Ex̃|x[max
d
Eθ|x,x̃{NB(d, θ)}] − max
d
Eθ|x{NB(d, θ)}, (2)
where the first term is the expected value of a decision based on our beliefs about θ given both new data, x̃,
collected between t1 and t2, and data, x, collected between time zero and t1. The second term is the expected
value of a decision based on our beliefs about θ given only the information collected up until t1. See Appendix
A for a fuller explanation.
Specifying current beliefs about model parameters for an ongoing study
The distribution for the cost-effectiveness model parameters given knowledge at t1 p(θ|x) can be defined
either in a fully Bayesian manner, by updating (possibly vague) prior information about θ with data x, or
by fitting a standard frequentist statistical model to x and obtaining the maximum likelihood estimate for
θ along with some expression of uncertainty, and treating this as a Bayesian posterior. In the absence of
strong prior information about θ, the two methods will produce very similar distributions for p(θ|x), even
with relatively little data.13
Specifying the likelihood for ongoing time-to-event data and left-truncation
To compute EVSI we must define the data-generating distribution for the follow-up data between t1 and t2,
p(x̃|θ). We first consider the structure of the data we will observe. We assume our study has two arms: new
treatment and standard care, and that N participants are recruited into each arm. Data, x, collected from
time zero to t1 take the form of a vector of times-to-death, -end of follow-up or -loss to follow-up, whichever is
soonest. Survival times for those alive at t1 are censored. If we continue to collect data x̃ from t1 to t2 we
may observe times-to-death for the participants whose observations were censored at t1. Survival times for
those alive at t2 or lost to follow-up are now the only observations censored. Table 1 illustrates the structure
of the data for one arm of a study with follow-up at 12 and 24 months.
Table 1: The structure of the data for one arm of a study with follow-up at 12 and 24 months. Five participants
are shown. Data are denoted x = {(9.3, 12, 12, 6.7, 12), (1, 0, 0, 0, 0)} for observations up until t1 = 12 months,
and x̃ = {(13.4, 24, 15.9), (1, 0, 0)} for observations between t1 and t2 = 24 months.
Follow-up up at t1 = 12 months Follow-up at t2 = 24 months
ID Survival time Censoring indicator, δ At risk at t1 Survival time Censoring indicator, δ Outcome
1 9.3 1 No - - Died at 9.3 months
2 12.0∗ 0 Yes 13.4 1 Died at 13.4 months
3 12.0∗ 0 Yes 24.0∗ 0 Alive at 24.0 months
4 6.7∗ 0 No - - LFU at 6.7 months
5 12.0∗ 0 Yes 15.9∗ 0 LFU at 15.9 months
*Observation censored (δ = 0). LFU = Lost to follow-up.
Survival times are usually assumed to arise from a data generating process that can be described using a
parametric model, the form of which must be chosen by the analyst.14 Censoring is common when collecting
time-to-event data, since the follow-up time may not be long enough to observe the endpoint of interest for all
individuals in the trial, and some individuals may be lost to follow-up.15 The likelihood function for survival
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where i indexes the n1 = N study participants at risk at time zero, where the censoring indicator δi = 1 when
xi is an observed event, δi = 0 when xi is a censored observation, and where θ are the parameters of the
survival distribution. The observed dataset at time point t1 consists of the n1 survival times and censoring
indicators, x = {x1, . . . , xn1 , δ1, . . . , δn1}.
The data collected between time points t1 and t2 is denoted x̃ = {x̃1, . . . , x̃n2 , δ̃1, . . . , δ̃n2}, where n2 is the
number of study participants at risk at t1. The likelihood function for x̃ is left-truncated at t1 to reflect that
events beyond t1 are conditional on not having occurred prior to t1.
16 Unlike censoring, which contributes to
the likelihood by plugging in a survival factor for censored observations as well as observed survival times,
truncation does not add any data points to the likelihood. This distinction is important, since we want to
avoid double counting the observed data x when we compute the likelihood for the ongoing study data x̃.
The left-truncated likelihood has an additional term in the denominator that re-normalises the truncated
distribution so that it integrates to 1, i.e.








Once we have derived the posterior distribution for the model parameters given data at t1, p(θ|x), and the
likelihood for the ongoing follow-up data, pLT (x̃|θ), we require a method for actually computing expression
(2). In almost all realistic applications this will require numerical methods. Nested Monte Carlo can be used,
but this is computationally expensive. A regression-based approach is much quicker,10 and this is described
along with the Monte Carlo approach in Appendix B.
We are now in a position to describe methods for computing EVSI that account for uncertainty about the
choice of survival model.
Model-averaged EVSI for an ongoing study accounting for survival model uncer-
tainty
Survival model uncertainty and model averaging
In this section, “model” refers to the survival model for the time-to-event data p(x|θ), not the cost-effectiveness
model, NB(d, θ). In many real applications we will be uncertain about which survival model is most appropriate
and should be used to extrapolate the data beyond the observed follow-up period t1, though we may be
comfortable with proposing a candidate set of models, M = Mr, r = 1, . . . , R, that covers plausible
approximations of the data generating process, i.e. the set is M − open in the terminology used by Bernardo
and Smith (1994).17 In these circumstances, we may account for model uncertainty using predictive model
averaging, and average over model predictions using model weights based on each model’s predictive ability.18,19
After observing data x at time t1, we place probability weight P (Mr|x) on the rth model producing the best
predictions, with
∑R
r=1 P (Mr|x) = 1.
The net benefit function for decision option d given model Mr and parameters θr is denoted NB(d, θr, Mr).






Eθr|x,Mr NB(d, θr, Mr)P (Mr|x)
}
= EM|x[Eθr|x,Mr {NB(d, θr, Mr)}]
= Eθr,M|x{NB(d, θr, Mr)}, (5)
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and the optimal choice at time point t1 is the decision d that maximises this expectation.
EVSI for an ongoing study accounting for model uncertainty
Additional follow-up data x̃ will not only update our judgements about parameters, p(θr|x, x̃, Mr), but
will also update our judgements about the relative plausibility of each model, P (Mr|x, x̃), for each model
r = 1, . . . , R.
The EVSI for an ongoing study, where we average over models, is given by








Eθr,M|x{NB(d, θr, Mr)}, (6)
which is identical to (2), except that expectations are now taken over models as well as parameters (see
Appendix C for a derivation).
To compute (6) we will need a method for generating plausible datasets x̃ from p(x̃|x), the distribution of
the follow-up data given the observed data, which takes account of the fact that we now consider plausible a
number of different data generating models. We will also need to define model probabilities given observed
data, P (Mr|x), and then find a method for computing posterior model probabilities P (Mr|x, x̃), given each
sampled future plausible dataset x̃. We address the issue of defining model probabilities given observed data
first.
Deriving model probabilities given observed data up until t1
We assume that before we see the observed data x, that we are indifferent about the ‘correct’ model, so
P (Mr) = 1/R for all r. After we observe data x, we use the Akaike’s Information Criterion (AIC)
20 to derive
posterior model probabilities giving greater weight to models with better predictive ability (according to







AICr(x) = −2 log{p(x|θ̂r)} + 2ur.
The term θ̂r is the maximum likelihood estimate for the parameters of model Mr, and ur is the number of
parameters in model Mr.
Generating plausible ongoing follow-up datasets, x̃, that we may observe between t1 and t2
Plausible datasets from the distribution p(x̃|x) are generated as follows. Firstly, we sample a model M (k)r
with probability P (Mr|x) given by Equation (7). Next, we draw a sample θ(k)r from the distribution of the
parameters of our chosen model p(θr|x, M (k)r ). Finally, we generate a dataset x̃(k) from the distribution of the
data p(x̃|θ(k)r , M (k)r ) given the sampled parameter values θ(k)r and model M (k)r . We can repeat this process
k = 1, . . . , K times to generate an arbitrary number of datasets.
Updating model probabilities given ongoing follow-up data from t1 to t2
We can derive our posterior model probabilities at time point t2, for dataset x̃
(k), via Bayes theorem:













We use bridge sampling to approximate the marginal likelihood, which is a form of importance sampling that
has been shown to give good approximations in a wide range of settings.21–24 The key notion behind bridge
sampling is that the marginal likelihood can be written as the ratio of two expectations, each of which can
be estimated via importance sampling. The name ‘bridge’ reflects the incorporation in the estimator of a
density function that ‘bridges’ (i.e. has good overlap with) the two densities from which samples are drawn. A
detailed tutorial on the bridge sampling method is given in the article by Gronau et al. (2017)23, and the
method is straightforward to implement in the R package bridgesampling25. Given the bridge sampling
estimates of p(x̃(k)|Mr, x) for each model, posterior model probabilities are trivial to compute via expression
(8).
As with single-model EVSI, computing model-averaged EVSI (expression 6) will require numerical methods.
Nested Monte Carlo and a regression-based approach are described in Appendix D. In the next section, we
will apply these methods in a synthetic case study.
Synthetic case study
We will model survival with and without accounting for survival model uncertainty.
Decision problem and model definition
Our decision problem is to determine which of two treatment options has the longest mean survival; a new
treatment (d = 1), or standard care (d = 2).
In the single-model case, survival is assumed to follow a Weibull distribution, and the net benefit of each
treatment option is assumed to equal the restricted mean survival time, given an overall time horizon of













where the model parameters are the log-transformed Weibull shape and scale parameters, θd = (θkd, θλd).
Computing restricted mean survival for distributions other than the exponential requires numerical integration,
but easy-to-use functions are available in the R package flexsurv.26
In the model-averaged case, the decision problem is as above, but we assume we are uncertain about the
choice of survival model, Mr, to extrapolate the observed data beyond the current follow-up period t1. We
assume that our set of plausible models M contains the following four parametric distributions: Weibull
(r = 1), Gamma (r = 2), Lognormal (r = 3), and Log-logistic (r = 4).
Generating synthetic case study datasets, x, collected up to t1 = 12 months
We generated two synthetic case study datasets: one in which the hazard of death is monotonically increasing,
and the other in which it is monotonically decreasing. For each case study we generated a dataset with 200
participants per trial arm with a maximum follow-up of t1 = 12 months. We denote the datasets x1 for new
treatment and x2 for standard care.
To explore the performance of the method when the survival model was mis-specified we generated survival times
evenly spaced from either a Weibull or a Gamma distribution, using the 0.005th, 0.015th, . . . , 0.985th, 0.995th
quantiles from each distribution (i.e. 100 evenly spaced quantiles that avoid 0 and 1). We could have randomly
generated survival times, but this would have just added additional Monte Carlo error when assessing the
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methods for computing EVSI. The parameters of the Weibull and Gamma distributions that we used to
generate the synthetic case study datasets are shown in Table 2.
Table 2: Weibull and Gamma distribution parameters for the synthetic case study
datasets
Increasing hazard case study Decreasing hazard case study
New treatment Standard care New treatment Standard care
Weibull shape, k 1.10 1.10 0.60 0.60
Weibull scale, λ 70.00 50.00 80.00 57.00
Gamma shape, α 1.80 1.80 0.80 0.80
Gamma rate, β 0.04 0.04 0.01 0.01
We enrolled all patients in the trial at t0 = 0, and right-censored the datasets at t1 = 12 months. We assumed
no loss to follow-up and did not apply any other censoring. Figure 1 shows Kaplan-Meier plots for the two
synthetic case study datasets.




























0 3 6 9 12
Time
200 196 190 182 175
200 194 187 178 169−−
Number at risk
200 181 170 161 154
200 178 166 157 149−−
Number at risk
Figure 1: Kaplan-Meier plots for the increasing hazard dataset (left) and decreasing hazard dataset (right)
Initial trial analysis at t1 = 12 months
For each synthetic case study, we analysed the two trial arms separately. We fitted all four models to the
data from each arm and estimated the model parameters using maximum likelihood (as implemented in the
flexsurvreg function).26 We assumed that our judgements about the log-transformed parameters for each
survival model conditional on the observed data up to t1, p(θr|x), are represented by a bivariate Normal
distribution with the mean vector and covariance matrix derived from the maximum likelihood estimation.
We computed the AIC for each model fit and derived model probability weights via Equation (7).
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Net benefits, AICs and model probabilities are shown in Table 3, and means and covariances for each model
are reported in Appendix G.
Table 3: Mean survival, Akaike’s Information Criterion and prior model probabilities P (Mr|x) for
the two hypothetical datasets








Weibull 50.96 277.58 0.26 84.81 437.06 0.29
Gamma 57.71 277.57 0.26 74.41 437.08 0.29
Lognormal 110.43 277.97 0.22 123.49 438.45 0.14
Log-logistic 79.28 277.58 0.26 105.98 437.14 0.28
Weighted average 72.93 93.31
Standard care
Weibull 44.01 329.26 0.28 77.85 470.37 0.30
Gamma 49.42 329.29 0.28 66.99 470.40 0.29
Lognormal 98.43 330.18 0.18 116.25 472.01 0.13
Log-logistic 71.00 329.33 0.27 99.70 470.47 0.28
Weighted average 62.36 85.85
Incremental values
Weighted average 10.57 7.46
AIC, Akaike’s Information Criterion.
The expected net benefits (mean survival times) assuming a single Weibull model computed via Equation
(9) are 50.96 versus 44.01 months (incremental = 6.95 months) for the increasing hazard dataset, and 84.81
versus 77.85 months (incremental = 6.97 months) for the decreasing hazard dataset. The Expected Value of
Perfect Information (EVPI) values, computed via Monte Carlo simulation with a sample size of 105, are 4.93
and 6.33 months for the increasing and decreasing hazard dataset, respectively.
The model-averaged net benefits, weighted by model probabilities, are 72.93 versus 62.36 months (incremental
= 10.57 months) for the increasing hazard dataset, and 93.31 versus 85.85 months (incremental = 7.46
months) for the decreasing hazard dataset. The model-averaged EVPI values are 10.32 and 9.97 months for
the respective datasets.
Generating plausible ongoing follow-up datasets, x̃, for the EVSI computation
Both the nested Monte Carlo and regression-based EVSI methods require a set of sampled ongoing follow-up
datasets for each trial arm, denoted x̃1 and x̃2. We generated k = 1, . . . , K datasets with K = 6,000 for each
trial arm, where the kth dataset was generated as follows.
In the single-model case, we first sampled log-shape and log-scale values, (θ
(k)
1 for new treatment and θ
(k)
2 for
standard care), from the bivariate Normal distributions in Appendix G. We computed the net benefit for each
decision option, given the sampled parameters, NB(d, θ
(k)
d ) and stored this (these values are required for the
regression-based approximation). For each arm, we then sampled n survival times from a truncated Weibull
distribution (see Appendix E) with the sampled shape and scale values where n was the number of patients
who were still alive in the trial arm at t1 = 12 months. Finally, survival times were censored at the proposed
endpoint for the ongoing data collection, t2.
In the model-averaged case, we first chose a model M
(k)
r with probability P (Mr|x), before sampling θ(k)r from
the bivariate Normal distribution p(θr|x) for the chosen model M (k)r and generating the n survival times for
each arm. The remainder of the data generation step is as above.
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Computing EVSI for ongoing follow-up via nested Monte Carlo
To sample from the posterior distributions, p(θd|xd, x̃(k)d ), we used Hamiltonian Monte Carlo (HMC) as
implemented in the package rstan27. HMC is a Metropolis-Hastings MCMC algorithm with a particularly
efficient sampling scheme that reduces Monte Carlo sampling error, therefore requiring fewer posterior samples
for any inference. The package rstan is an R interface to the Stan language.28 An alternative option would
have been to use OpenBUGS.29
In the single-model case, for each outer loop sampled dataset, k = 1, . . . , 6,000.00, we averaged the net benefit
functions over J = 2,000.00 inner loop posterior samples of the model parameters, and stored the maximum
net benefit of the two treatment options. We then averaged these maximised net benefits and subtracted the
expected value of a decision based on current information to obtain the EVSI following expression (14) in
Appendix B.
In the model-averaged case, for each outer loop dataset, we generated the J posterior samples of the model
parameters for each of the r = 1, . . . , 4 models (we needed to identify the truncated likelihood function for
each model as we did for the Weibull example above, but this is straightforward. See Appendix E). We
weighted the parameter averaged net benefits NBkr (d) by the posterior model probabilities P (Mr|x̃(k)) to
give the posterior model-averaged expected net benefit, and identified the treatment d that maximized this
for iteration k = 1, . . . , 6,000.00. We then subtracted the expected value of a decision based on current
information to obtain the EVSI following expression (23) in Appendix D.
Computing EVSI for ongoing follow-up via regression
The GAM approach to computing EVSI for extending the follow-up until time t2 for the hypothetical example
is as follows.
For each trial arm, we computed a low dimensional summary statistic for each dataset. A convenient
choice here is the number of observed events e
(k)
d and the total time at risk y
(k)









d } for d = 1, 2.
Then, for each of the two decision options, we fitted a GAM regression model with the stored net benefits
NB(d, θ
(k)




d as independent variables.
We allowed a smooth, arbitrary, non-linear relationship between the independent and dependent variables,
plus arbitrary interaction between the independent variables, by specifying a ‘tensor product’ cubic regression
spline basis for the independent variables. This has the simple syntax gam(nb_d ~ te(e_d, y_d)) in the
mgcv30 package in R. We extracted the GAM model fitted values ĝ
(k)
d from each regression model fit, and
estimated the EVSI using Equation (18) in Appendix B.
The GAM-based approximation method for model-averaged EVSI is identical to that used in the single-model
case.
Results
EVSI values for the Weibull ongoing data
The nested Monte Carlo- and GAM-based EVSI estimates for additional follow-up times of 12, 24, 36, and 48
months (i.e. t2 = 24, 36, 48, 60 months) are shown in Table 4. The methods used to estimate the standard
errors of the nested Monte Carlo and GAM estimators are described in an appendix of the article by Strong,
Oakley, and Brennan (2014).31
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Table 4: EVSI (SE) values for additional follow-up time for the two hypothetical datasets given
a Weibull distribution for the survival times








12 4.25 (0.09) 4.28 (0.08) 4.41 (0.10) 4.46 (0.10)
24 4.58 (0.09) 4.62 (0.06) 5.20 (0.11) 5.27 (0.09)
36 4.68 (0.09) 4.71 (0.05) 5.45 (0.11) 5.54 (0.08)
48 4.74 (0.09) 4.77 (0.04) 5.55 (0.11) 5.65 (0.07)
GAM, Generalized Additive Model. EVPI values are 4.93 and 6.33, respectively. Total computation
times for the analyses in the table are 24,808 seconds (Nested Monte Carlo) and 36 seconds (GAM).
As expected, the EVSI reflects diminishing marginal returns for increasing follow-up duration and converges
towards the EVPI. The EVSI varies depending on the underlying hazard pattern, even when point estimates
of mean incremental survival benefit are similar (6.95 months for the increasing hazard dataset and 6.97
months for the decreasing hazard dataset). The increasing hazard dataset has lower numbers of prior observed
events and higher expected numbers of future events for the additional follow-up time than the decreasing
hazard dataset, which - all else equal - is expected to result in greater EVSI values. This upwards effect on
EVSI is however canceled out by the downwards effect of lower estimates of mean survival, resulting in greater
EVSI values for the decreasing hazard dataset than for the increasing hazard dataset.
The GAM method agrees well with the MCMC method, with the benefit of a greatly reduced computational
cost. The MCMC inner loop for the Monte Carlo method used parallel processing, but even with this
additional efficiency, the regression method was approximately 700 times faster than the nested Monte Carlo
method. We used a machine running Windows 10 with an Intel® CoreTM i9 CPU with 15 threads running on
8 cores at 2.40GHz, and with 32 GB RAM.
Of note is that the standard errors for the nested Monte Carlo estimator slightly increase with increasing
follow-up duration, while the opposite is true for the GAM estimator. This is due to different mechanisms
through which the effective sample size of the generated data x̃ affects the standard errors of the nested Monte
Carlo and GAM estimators, which is further explained in Appendix F.
Model-averaged EVSI values
The nested Monte Carlo- and GAM-based model-averaged EVSI estimates for additional follow-up times of
12, 24, 36, and 48 months (i.e. t2 = 24, 36, 48, 60 months) are shown in Table 5.
Table 5: EVSI (SE) values for additional follow-up time for the two hypothetical datasets given
a Weibull distribution for the survival times








12 7.50 (0.18) 7.52 (0.14) 6.69 (0.15) 6.70 (0.13)
24 8.75 (0.20) 8.82 (0.10) 8.09 (0.18) 8.16 (0.11)
36 9.43 (0.21) 9.44 (0.08) 8.71 (0.19) 8.76 (0.09)
48 9.77 (0.22) 9.74 (0.07) 8.96 (0.19) 9.01 (0.08)
GAM, Generalized Additive Model. EVPI values are 10.32 and 9.97, respectively. Total computation
times for the analyses in the table are 289,211 seconds (Nested Monte Carlo) and 37 seconds
(GAM).
As expected, the EVSI converges towards the EVPI as follow-up time increases, and there is good agreement
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between the two methods. The model-averaged EVSI values for additional follow-up are greater than the
Weibull model EVSI (Table 4), which reflects the additional value in reducing model as well as parameter
uncertainty. The GAM method is approximately 8,000 times faster than the nested Monte Carlo method.
Expected Net Benefit of Sampling
The net value of additional data collection can be quantified by computing the Expected Net Benefit of
Sampling (ENBS).32 In the context of an ongoing study, the ENBS is the difference between the EVSI for
collecting additional data between t1 and t2 and the expected cost of continuing the study and potential
health benefits foregone if approval is withheld. When the ENBS is positive, it is worthwhile to continue
the study and collect more data before making an adoption decision. If the adoption decision is reversible,
approval can be granted while additional data is being collected. This is referred to as “approval with research”
(AWR).6 If the adoption decision is irreversible, approval should be withheld until the additional data has
been collected, which is referred to as “only in research” (OIR).
Figure 2 illustrates that when approval is reversible and AWR can be recommended, the marginal benefit
in terms of model-averaged EVSI equals the marginal cost of continuing the trial at 47 and 50 months of
additional follow-up for the increasing and decreasing hazard datasets, respectively. These are the time points
at which the ENBS is at a maximum. When approval is irreversible and OIR is recommended, the ENBS is at
a maximum when the marginal benefit of delaying the decision until more data has been collected equals the
marginal cost of continuing the trial and withholding approval, which is at 20 and 24 months of additional
follow-up for the increasing and decreasing hazard datasets, respectively.
MBEVSI MCAWR MCOIR
 t * = 47























 t * = 50






12 36 60 84
Additional follow−up (months)
Figure 2: Marginal benefit (MBEVSI), marginal cost of ‘approval with research’ (MCAWR) and marginal cost
of ‘only in research’ (MCOIR) given different durations of additional follow-up. Estimates are based on the
model-averaged EVSI analyses for the increasing hazard dataset (left) and decreasing hazard dataset (right),
trial costs of 5 life months per month, 5 new patients receiving treatment each month and a decision time
horizon of 10 years.
Discussion
EVSI is useful not only for informing the design of a future trial, but also for deciding whether an ongoing
study should continue in order to collect additional data before making an adoption decision. This article is
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the first to set out generic EVSI algorithms for survival data from an ongoing trial with or without accounting
for survival model uncertainty. The EVSI algorithms generalise to any decision context in which structural
uncertainty is present, provided that the analyst is able to derive probability weights for the competing
scenarios.
Strengths and limitations
The nonparametric regression-based method is fast and straightforward to implement, even when we include
consideration of model uncertainty. In fact, extending the method to include model uncertainty does not
increase the complexity or computation time. The nested Monte Carlo procedure, on the other hand, is
extremely computationally demanding when we include model uncertainty.
When a large part of the relevant time horizon is unobserved, the clinical plausibility of the survival
extrapolations is often of greater importance than the mathematical fit to the observed data.14 Deriving prior
model probabilities from purely statistical measures such as AIC may therefore not always be appropriate
when data are immature, since these measures do not reflect the plausibility of the extrapolations.8 This
became evident in the hypothetical case studies, as the AIC-based prior model probabilities of the lognormal
and log-logistic models were similar to those of the Weibull and Gamma models for the increasing hazard
dataset, despite the fact that the former two models do not allow for monotonically increasing hazards and
therefore cannot capture the true underlying hazard pattern.
An alternative approach to dealing with model uncertainty could be to consider a single very flexible model
that includes all the models the analyst believes plausible. For example, the Generalized F distribution
includes most commonly used parametric survival distributions as special cases.33 It is however more common
to view model uncertainty as structural uncertainty in choosing between competing survival models.9,34
Furthermore, the use of a very flexible model requires the specification of a prior that appropriately reflects
uncertainty in choosing between alternative functional forms within the flexible model, which may be not be
straightforward. Flexible models such as the Generalized F distribution are also prone to overfitting and may
not always provide reliable predictions of mean survival, particularly when data is immature.9
Although we did not consider flexible parametric models such as Royston-Parmar spline-based models35 or
mixture cure models36 in our case studies, the principles outlined in this article apply to any parametric
survival model.
In the synthetic case studies, we assumed all patients had the same follow-up at t1. In clinical trials, patients
are usually recruited over a period of time, which means the individual follow-up times will vary at t1. In these
circumstances, additional follow-up will not only provide more information about the tail of the survival curve
(from patients that were enrolled early), but also about the central part (from patients that were enrolled
later).
We did not consider sequential trial designs37, which require EVSI to be recalculated after each observation
and to account for all the possible ways in which future patients may be allocated to the trial arms or when
to stop the trial.38 This can give rise to a large number of subproblems that may have to be solved using
dynamic programming methods, which can be computationally very demanding.
Policy implications
Immature evidence leads to a high level of decision uncertainty, which may result in the uptake of technologies
that reduce net health benefit. The decision making context in which trials are ongoing and evidence is
immature is particularly pronounced for new oncology drugs. The purpose of the Cancer Drug Fund (CDF) in
the UK, for example, is to enable early patient access to promising new cancer drugs while allowing evidential
uncertainty to be reduced through ongoing data collection. In the period between 2017 and July 2018, the
National Institute for Health and Care Excellence (NICE) recommended over half of the appraised cancer
drugs through the CDF, typically due to concerns about immature survival data.39
The EVSI algorithms in this article can help decision makers determine whether early patient access to a
new technology can be justified on the basis of the current evidence or whether more mature evidence is
needed. The option to enroll more patients into an ongoing trial should also be considered if it has a positive
12
net value. Unlike most of the existing work on EVSI that primarily targets commissioners and funders of
research, EVSI for ongoing trials also addresses the policy context of decision makers who do not have the
remit to commission additional research.
Data Availability
The analysis code used in this study is available from Github at https://github.com/matverv/evsi-survival-
ongoing-trial.
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Appendices
Appendix A - Deriving an expression for the EVSI for an ongoing study assuming
no model uncertainty
Before the study starts, we have only prior knowledge about model parameters, which we represent via
the distribution p(θ). In many cases we will not have strong prior information, and p(θ) will therefore be
minimally informative (typically flat on some scale).
We collect data x during an initial period of follow-up that extends up until time t1. At t1 we update our
judgements about θ, conditional on x to give the posterior distribution p(θ|x). The question is, should we
continue the study to collect more data before making an adoption decision?




Further data collection up until time point t2 will give us additional data x̃, which we can use to update




At time point t1 data x̃ are as yet uncollected, however we can take the expectation of expression (11) with





The EVSI for continuing the study from t1 to t2 is the difference between the expected value of a decision
made after collecting data up to t2, expression (12), and the expected value of a decision based on observed
data collected up to t1, expression (10),
EVSI(ongoing study) = Ex̃|x[max
d




Appendix B - Methods for computing the EVSI for an ongoing study assuming
no model uncertainty
Nested Monte Carlo method for computing EVSI for an ongoing study
Calculating EVSI for an ongoing study requires evaluation of the expectation of a maximised conditional
expectation, Ex̃|x[maxd Eθ|x,x̃{NB(d, θ)}]. This will rarely have an analytic solution. A nested expectation



























In this scheme, we generate samples from p(x̃|x) in the ‘outer loop.’ We do this by first sampling θ(k), k =
1, . . . , K from p(θ|x), and then sampling x̃(k) from the truncated likelihood pLT (x̃|θ(k)). For each sample
x̃(k), we then sample values θ(j,k), j = 1, . . . , J from the posterior distribution p(θ|x, x̃(k)) in the ‘inner loop’.
Unless p(LT x̃|θ) and p(θ|x) are conjugate, which will be rare in practice, then sampling from p(θ|x, x̃(k)) will
require Markov Chain Monte Carlo (MCMC) or a similar scheme. The total number of samples required for
each d is J × K.
Note that the second term in expression (14) has a nested double loop structure, even though the target
estimand is the single maximised expectation maxd Eθ|x{NB(d, θ)}. We reuse the same samples for both
terms in the EVSI expression in order to reduce Monte Carlo error, noting that maxd Ex̃|x[Eθ|x,x̃{NB(d, θ)}] =
maxd Eθ|x{NB(d, θ)} by the law of total expectation.10
Regression-based method for computing EVSI for an ongoing study
Strong and others (2015)10 developed a fast, non-parametric regression-based method that greatly reduces
the computational burden of the nested Monte Carlo procedure to EVSI. Their approach relies on estimating
the functional relationship between the posterior expected net benefits and the generated datasets, thereby
avoiding the inner loop and markedly increasing efficiency over the nested Monte Carlo method.
In the regression approach, we first generate a random parameter vector θ(k) from the distribution of model
parameters p(θ|x) at time point t1, and a random data sample x̃(k) from the truncated likelihood pLT (x̃|θ(k)),
where k indicates the kth sample. The net benefit is evaluated at the same k
th sample of the model parameters,
NB(d, θ(k)). We then express the observed net benefit NB(d, θ(k)) as a sum of the conditional expectation of
the net benefit given the data, Eθ|x,x̃(k){NB(d, θ)}, which we wish to estimate to evaluate the EVSI (Equation
(2)), and a mean-zero error term, ε(k),
NB(d, θ(k)) = Eθ|x,x̃(k){NB(d, θ)} + ε(k). (15)
As explained by Strong and others (2015)10, we can think of the conditional expectation Eθ|x,x̃(k){NB(d, θ)}
as an unknown function of x̃(k). We denote this function g(d, x̃(k)) and substitute this into Equation (15),
giving
NB(d, θ(k)) = g(d, x̃(k)) + ε(k). (16)
Since x̃ is a vector of (possibly censored) time-to-event data, and therefore high-dimensional, we write the the
function g in terms of a low-dimensional summary statistic of the data T (x̃),
NB(d, θ(k)) = g{d, T (x̃(k))} + ε(k). (17)
We then use a generalized additive model (GAM), which is a flexible non-parametric regression model, to
estimate the target function g. This means that we fit a GAM model to each decision option d and extract

























Appendix C - Deriving an expression for the EVSI for an ongoing study account-
ing for model uncertainty
In the model averaging setting, additional follow-up data x̃ will update our judgements about both parameters
and the relative plausibility of each model.
The net benefit function for decision option d given model Mr and parameters θr is denoted NB(d, θr, Mr).







Eθr|x,Mr NB(d, θr, Mr)P (Mr|x)
}
= EM|x[Eθr|x,Mr {NB(d, θr, Mr)}]
= Eθr,M|x{NB(d, θr, Mr)}, (19)
and the optimal choice at time point t1 is the decision d that maximises this expectation.
The net benefit after observing ongoing follow-up data x̃ between t1 and t2 is





Eθr|x,x̃,Mr NB(d, θr, Mr)P (Mr|x, x̃)
}
= Eθr,M|x,x̃{NB(d, θr, Mr)}, (20)
and the optimal choice at time point t2 is the decision d that maximises this expectation. Follow-up data x̃
are not available at t1, but we can compute the expected value of the maximised net benefit based on our








The EVSI for an ongoing study, where we average over models, is then the difference between (21) and the
maximised value of (19),








Eθr,M|x{NB(d, θr, Mr)}. (22)
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Appendix D - Methods for computing model-averaged EVSI for an ongoing study
Nested Monte Carlo method for computing model-averaged EVSI
The nested double-loop Monte Carlo scheme in expression (14) naturally extends to the nested triple loop
scheme when we average over models as well as over parameters and datasets,







































r |x, x̃(k)). (23)
In this (somewhat intimidating looking) scheme, we first generate k = 1, . . . , K samples x̃(k) from p(x̃|x) in
the ‘outer loop’ (as described in the generating datasets section above). Then, in the inner loop, we compute
posterior expected net benefits by drawing j = 1, . . . , J samples θ
(j,k)
r from p(θr|x, x̃(k), M (k)r ) and take the
average for each treatment d. This inner loop sampling from the posterior distribution of the parameters
typically requires MCMC, unless the prior and truncated likelihood are conjugate. Finally, for each k, we
compute the posterior model probability P (M
(k)
r |x, x̃(k)) for each model r = 1, . . . , R (again, as described
above).
As before, we reuse the same samples for both terms in the EVSI expression in order to reduce Monte Carlo
error, noting that maxd Ex̃|x(EM|x,x̃[Eθr|x,x̃,Mr {NB(d, θr, Mr)}]) = maxd Eθr,M|x{NB(d, θr, Mr)} by the law
of total expectation. The total number of samples required for each d is J × R × K.
The nested triple-loop Monte Carlo scheme for computing model-averaged EVSI is given in Box 1.
Box 1: Nested Monte Carlo Scheme for Computing Model-Averaged EVSI
for k = 1, . . . , K outer loops do
Sample a model M
(k)
r given current data x with probability P (Mr|x)
Sample θ
(k)
r from the distribution of the parameters of the sampled model, p(θr|x, M (k)r )
Generate a new data sample x̃(k) from the distribution of the data p(x̃|θ(k)r , M (k)r )
for r = 1, . . . , R models do
Compute posterior expected net benefits by drawing j = 1, . . . , J inner loop samples θ
(j,k)
r from
p(θr|x, x̃(k), M (k)r ) and take the average for each decision option d
end
Compute the posterior model probabilities P (M
(k)
1 , . . . , M
(k)
R |x, x̃(k))
Find the decision option d that maximises model-averaged posterior expected net benefit for iteration k
end
Compute the expected value of a decision based on new data x̃ by taking the average of the maximum
expected net benefits over the K iterations
Compute the expected value of a decision based on current data x by finding the decision option d that
maximises the average of the expected net benefits over the K iterations
Compute the EVSI by subtracting the expected value of a decision based on current data from the
expected value of a decision based on new data
Regression-based method for computing model-averaged EVSI
The non-parametric regression-based method for computing model-averaged EVSI is a natural extension of
the regression-based method for a single known model described above. Firstly, we sample a model M
(k)
r
with probability P (Mr|x) given by Equation (7). Next, we draw a sample θ(k)r from the distribution of the
parameters of our chosen model p(θr|x, M (k)r ).
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We then generate a dataset x̃(k) from the distribution of the data p(x̃|θ(k)r , M (k)r ) given the sampled parameter
values θ
(k)
r and model M
(k)




r ) for each d. Repeating
this k = 1, . . . , K times gives us, for each d, a vector of K net benefits, and K corresponding datasets
x̃(1), . . . , x̃(K).




r ) as a sum of the posterior
expectation of the net benefit given dataset x̃(k) and a mean-zero error term,
NB(d, θ(k)r , M
(k)
r ) = Eθr,M|x,x̃(k){NB(d, θr, Mr)} + ε(k). (24)
We can think of the expectation Eθr,M|x,x̃(k){NB(d, θr, Mr)} as an unknown function of x̃(k), which we denote
g(d, x̃(k)). Substituting this into Equation (24) gives
NB(d, θ(k)r , M
(k)
r ) = g(d, x̃
(k)) + ε(k). (25)
This means that the posterior model-averaged net benefit can be expressed in terms of a single function g and
error term ε, independent of the number of models m considered in the analysis. We write the the function g
in terms of a low-dimensional summary statistic of the survival data T (x̃(k)),
NB(d, θ(k)r , M
(k)
r ) = g{d, T (x̃(k))} + ε(k). (26)
We then estimate the posterior model-averaged net benefit as before, by fitting a GAM model to each decision
option d and extracting the regression model fitted values ĝ
(k)
d . The model-averaged EVSI is then given by
Equation (18).
The GAM regression-based scheme for computing model-averaged EVSI is given in Box 2.
Box 2: Generalized Additive Model (GAM) Regression-Based Scheme for Computing Model-Averaged
EVSI
for k = 1, . . . , K outer loops do
Sample a model M
(k)
r given current data x with probability P (Mr|x)
Sample θ
(k)
r from the distribution of the parameters of the sampled model, p(θr|x, M (k)r )





Generate a new data sample x̃(k) from the distribution of the data p(x̃|θ(k)r , M (k)r )
Calculate a summary statistic T (x̃(k))
end




r ) on T (x̃(k)) for each decision option d using GAM
Extract the GAM fitted values ĝ
(k)
d for each d
Compute EVSI via Equation (18)
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Appendix E - Truncated likelihood functions for the Weibull, Gamma, Lognormal
and Log-logistic survival models
Note that we use the same parameterisations of the Weibull, Gamma, Lognormal and Log-logistic distributions
as in the R package flexsurv.26
Truncated likelihood function for the Weibull distribution
In order to compute EVSI via the nested Monte Carlo scheme described by Equation (14) we need to define
the Weibull truncated likelihood functions for the generated data: p(x̃
(k)
1 |θk1, θλ1) for new treatment and
p(x̃
(k)
2 |θk2, θλ2) for standard care.









The survivor function is




and the left-truncated likelihood function is therefore





























where x̃i and δ̃i are the survival time and censoring indicator for patient i, where censoring is at the proposed
new follow-up time of t2. The expressions above are similarly defined for standard care (d = 2) with θk2, θλ2
replacing θk1, θλ1, and x̃2 replacing x̃1.
Let i index the n1 = N study participants at risk at time zero, where the censoring indicator δi = 1
when xi is an observed event, δi = 0 when xi is a censored observation, and where θ are the parameters
of the survival distribution. The observed dataset at time point t1 consists of the n1 survival times and
censoring indicators, x = {x1, . . . , xn1 , δ1, . . . , δn1}. Denote the data collected between time points t1 and t2
as x̃ = {x̃1, . . . , x̃n2 , δ̃1, . . . , δ̃n2}, where n2 is the number of study participants at risk at t1. Events occurring
between t1 and t2 are conditional on not having occurred before t1.
Truncated likelihood function for the Gamma distribution









The survivor function is
S(x, θ) = 1 − γ(eθα , x),
where γ(eθα , x) is the lower incomplete gamma function, given by







We can define the left-truncated likelihood function for the Gamma distribution in terms of the density
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function and survivor function,





























1 − γ(eθα , x̃i)
}1−δ̃i







Truncated likelihood function for the Lognormal distribution















The survivor function is
S(x, θ) = 1 − Φ
(




where Φ is the cumulative distribution function of the standard normal distribution N (0, 1).





















and the left-truncated likelihood function is












































































Truncated likelihood function for the Log-logistic distribution
























and the left-truncated likelihood function is



































































Method for sampling from a truncated distribution
We can sample values from a truncated survival distribution that lie in the interval (t1, ∞) as follows. We
denote the cumulative density function evaluated at time t with parameters θ as F (t, θ). We first compute
the value of the cumulative density function at t1, p = F (t1, θ), (i.e. the probability that a survival time will
exceed t1). We then sample n values from a uniform distribution on the interval [p, 1], and plug these into the
corresponding inverse cumulative density function F −1 (·, θ). This results in n survival times greater than t1
that follow the required truncated survival distribution.
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Appendix F - The impact of increasing follow-up durations on the standard errors
of the MCMC and GAM estimators
Increasing follow-up durations affect the standard errors of the nested Monte Carlo and GAM estimators in
different ways. A longer duration of additional follow-up time will result in a greater effective sample size
(ESS) of the generated data x̃, as the number of observed events e and time at risk y will be greater. When
ESS → 0, the posterior expectation Eθ|x,x̃(k) will be similar to the prior expectation Eθ for all k, and the
variance of the posterior mean will therefore tend to 0. When ESS → ∞, the posterior expectation Eθ|x,x̃(k)
will be similar to the prior parameter sample θ(k) that was used to generate the data x̃(k) for all k, and the
variance of the posterior mean will therefore converge to the variance of θ. Thus, as the variance of the
posterior mean increases with increasing values for the additional follow-up time, the standard error of the
nested Monte Carlo estimator is expected to increase as well. The relation between the posterior and prior
variance as a function of sample size is further explained in a paper by Jalal & Alarid-Escudero (2018).40
The ESS affects the standard error of the GAM estimator differently. We recall that the GAM approach relies
on expressing the posterior expected net benefit as a function of the generated data x̃. When ESS → ∞,
the variance of the error term ε(k) in the expression NB(d, θ(k)) = Eθ|x,x̃(k){NB(d, θ)} + ε(k) will tend to 0,
since the posterior expectation Eθ|x,x̃(k) will be similar to the prior parameter sample θ
(k) that was used to
generate the data x̃(k) for all k. The smaller the variance of the error term ε(k), the greater the precision
with which the GAM regression coefficients can be estimated, and the smaller the variance of the regression
fitted values. Increasing the length of additional follow-up time increases the precision with which the GAM
regression coefficients are estimated, and consequently reduces the standard error of the GAM estimator.
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Appendix G - Maximum likelihood estimates for the model parameters
Table G1: Bivariate Normal distribution hyperparameters for the Weibull model
parameters given data collected up to t1 = 12 months
Parameter Mean, µ Covariance matrix, Σ
Case study 1: Increasing hazard dataset
Log shape for new treatment











Log shape for standard care











Case study 2: Decreasing hazard dataset
Log shape for new treatment











Log shape for standard care











Table G2: Bivariate Normal distribution hyperparameters for the Gamma model
parameters given data collected up to t1 = 12 months
Parameter Mean, µ Covariance matrix, Σ
Case study 1: Increasing hazard dataset
Log shape for new treatment











Log shape for standard care











Case study 2: Decreasing hazard dataset
Log shape for new treatment











Log shape for standard care












Table G3: Bivariate Normal distribution hyperparameters for the Lognormal
model parameters given data collected up to t1 = 12 months
Parameter Mean, µ Covariance matrix, Σ
Case study 1: Increasing hazard dataset
Meanlog for new treatment











Meanlog for standard care











Case study 2: Decreasing hazard dataset
Meanlog for new treatment











Meanlog for standard care











Table G4: Bivariate Normal distribution hyperparameters for the Log-logistic
model parameters given data collected up to t1 = 12 months
Parameter Mean, µ Covariance matrix, Σ
Case study 1: Increasing hazard dataset
Log shape for new treatment











Log shape for standard care











Case study 2: Decreasing hazard dataset
Log shape for new treatment











Log shape for standard care
Log scale for standard care
(
θs2
θη2
) (
−0.343
4.002
) (
0.017 −0.030
−0.030 0.104
)
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